Compounded Sema Injectable denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Requires Prior Authorization — and Why You Can Appeal a Denial

UnitedHealthcare requires prior authorization (PA) for compounded semaglutide injectable because the plan has determined the medication carries meaningful cost or utilization risk and warrants clinical review before coverage is approved. A PA denial — as opposed to a PA requirement — means a UHC clinical reviewer evaluated the submitted information and concluded the coverage criteria were not met. Most PA denials result from incomplete or insufficient documentation at the time of submission, not from a final clinical judgment that the treatment is wrong for you.

PA denials are strongly appealable, particularly when the clinical record is organized and complete.

## Your Federal Appeal Rights

Under ACA §2719 (non-grandfathered plans) you are entitled to independent external review after exhausting UHC's internal appeals. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review with access to every document, record, and criterion the plan used. The external-review window is generally open for approximately four months after a final internal denial. For urgent clinical situations, request an expedited 72-hour review — UHC must respond on that timeline.

## The Concrete Appeal Process

1. Request UHC's PA criteria for compounded GLP-1 injectables in writing — you are entitled to these under ERISA/ACA. 2. Identify precisely which criterion or criteria UHC states were not met. 3. File a Level 1 internal appeal with a complete clinical package addressing every PA criterion explicitly. 4. If the Level 1 appeal is denied, escalate to Level 2 and then to external IRO review (binding on UHC).

## Documentation to Gather

• Diagnosis confirmation — office notes, diagnostic test results, and ICD codes establishing the underlying diagnosis and its clinical basis.
• Clinical severity documentation — chart entries (with dates) showing the degree of illness, associated comorbidities, and the health impact that makes treatment medically necessary.
• Prior-treatment history with dates and outcomes — dated records for every prior treatment in the same therapeutic area: the agent used, duration, dose range tried, and the specific reason treatment was stopped or deemed inadequate (lack of efficacy, adverse effects, contraindication).
• Prescriber medical-necessity letter — a patient-specific letter from the treating clinician explaining the clinical rationale, referencing actual chart findings, and mapping those findings to UHC's published PA criteria. Generic letters are less effective than ones that directly address UHC's specific requirements.
• Relevant clinical guideline reference — the prescriber may reference the applicable professional society guideline by organization name (e.g., the relevant Obesity Medicine Association or Endocrine Society guidance) to support that the treatment is consistent with the standard of care.

## Criteria-Mapping Structure

Build a table using UHC's actual PA criteria:

| UHC Prior-Authorization Criterion | Chart Evidence That Satisfies It | |---|---| | [Copy each UHC PA criterion verbatim] | [Specific chart date, note, lab, or prescriber statement meeting that criterion] |

Submitting a criteria-mapped appeal package eliminates vagueness from the review and forces UHC to identify any specific remaining gap — rather than issuing a second blanket denial. The prescriber letter and criteria table together form the strongest possible PA appeal submission.